First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-MuscleInvasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations